Clinical Scorecard: How Harrow Brought Triesence Back to Market
At a Glance
| Category | Detail |
|---|---|
| Condition | Ocular inflammatory conditions unresponsive to topical corticosteroids |
| Key Mechanisms | Visualization during vitrectomy, unique formulation with defined particle size range |
| Target Population | Retina surgeons and patients requiring ocular treatment |
| Care Setting | Ophthalmic care settings |
Key Highlights
- Triesence was unavailable in the US for over 2 years due to supply chain issues.
- Harrow acquired Triesence in January 2023 and relaunched it in October 2024.
- The product meets current Good Manufacturing Practice standards.
- A 5-year strategic supply agreement ensures continued production.
- Educational programs support the reintroduction of Triesence to the ophthalmic community.
Guideline-Based Recommendations
Diagnosis
- Assess ocular inflammatory conditions that are unresponsive to topical corticosteroids.
Management
- Utilize Triesence for treatment and visualization during surgical procedures.
Monitoring & Follow-up
- Conduct regular assessments of supply chain integrity and product quality.
Risks
- Potential reliance on compounded products or off-label options during shortages.
Patient & Prescribing Data
Patients with ocular inflammatory conditions requiring corticosteroid treatment.
Triesence provides a reliable option for patients when topical treatments fail.
Clinical Best Practices
- Ensure clear communication and education regarding Triesence availability.
- Engage in peer-to-peer learning opportunities for less experienced surgeons.
- Maintain redundancy in the supply chain for critical components.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.